FGFR2 rs2981582: What Your Genotype Means
The rs2981582 variant is a single nucleotide polymorphism located within the FGFR2 gene. It is widely recognized in genomic research as a common genetic risk factor associated with an increased susceptibility to breast cancer, specifically estrogen receptor-positive (ER+) subtypes.
What each genotype means
Lower breast cancer risk
This genotype is associated with a lower statistical risk of developing breast cancer compared to those carrying the T allele. Research indicates that the C allele is linked to lower levels of FGFR2 transcription in breast tissue. This finding is based on population-level studies and does not predict individual health outcomes.
This genotype is common in many populations, though frequencies vary significantly by ancestry.
Intermediate breast cancer risk
Carrying one copy of the T allele is associated with a statistically higher risk of breast cancer compared to the CC genotype. The T allele has been linked to increased FGFR2 gene expression in breast tumors. This association is observed at the population level and should be discussed with a healthcare provider in the context of your overall health history.
This heterozygous genotype is frequently observed in populations of European descent, where the T allele is common.
Higher breast cancer risk
This genotype is associated with the highest statistical risk for breast cancer among the three possible combinations for this variant. Studies suggest the T allele may lead to increased FGFR2 transcription, which is a known factor in breast cancer susceptibility. This information is for educational purposes and does not constitute a medical diagnosis.
This genotype is found in a significant portion of the population, particularly among individuals of European ancestry.
Understanding the rs2981582 Variant
The rs2981582 variant is a specific change in the DNA sequence located within the FGFR2 gene. In genetic terms, it is a single nucleotide polymorphism (SNP), meaning a single "letter" of the genetic code—either a C or a T—differs between individuals at this specific position. This variant is situated in the second intron of the FGFR2 gene. Introns are non-coding regions of a gene that do not provide instructions for making proteins directly, but they often play critical roles in regulating how genes are expressed. Research suggests that this specific location may influence the activity levels of the FGFR2 gene in breast tissue, potentially affecting how cells grow and divide.
The Role of the FGFR2 Gene
The FGFR2 gene provides instructions for creating the Fibroblast Growth Factor Receptor 2 protein. This protein acts as a cell-surface receptor, functioning like a docking station that receives signals from outside the cell to trigger internal processes. It is essential for normal embryonic development, including the formation of limbs, lungs, and skin. Beyond development, the receptor is involved in regulating cell proliferation, differentiation, and apoptosis (programmed cell death). Because it helps control these fundamental cellular behaviors, variations that alter the expression or function of FGFR2 can have significant biological consequences. In the context of breast tissue, the regulation of this receptor is closely linked to the pathways that govern cell growth.
Research and Breast Cancer Associations
The association between rs2981582 and breast cancer is one of the most replicated findings in breast cancer genomics. Large-scale genome-wide association studies (GWAS) have consistently identified this SNP as a risk factor. The evidence is considered moderate to strong, with the T allele being associated with a higher risk of developing breast cancer. Notably, this risk is most pronounced in estrogen receptor-positive (ER+) breast cancer, where the presence of the T allele is linked to increased susceptibility. Some studies have also explored how this variant interacts with other genetic factors, such as BRCA1 and BRCA2 mutations, suggesting that rs2981582 may modify the risk profile for individuals who already carry those high-risk mutations. It is important to note that this is a statistical association observed in populations, not a direct cause of disease.
Population Frequency
The rs2981582 variant is common across many populations. In European ancestries, the minor allele frequency is approximately 40%. Because it is a common variant, a large portion of the population carries at least one copy of the risk-associated allele. While the frequency is well-documented in European cohorts, research has also confirmed its relevance in various other ethnic groups, including studies involving Chinese and Mexican populations. The widespread prevalence of this variant highlights its status as a common genetic marker rather than a rare mutation. Understanding its frequency helps researchers contextualize its contribution to the overall genetic architecture of breast cancer risk across diverse human populations.
What This Information Means for You
Knowing your genotype for rs2981582 provides insight into your genetic predisposition, but it is not a diagnostic tool. Genetic risk factors are only one piece of a much larger puzzle that includes lifestyle, environment, and other genetic markers. Having a higher-risk genotype does not mean you will develop breast cancer, nor does having a lower-risk genotype guarantee you will not. This information should not be used to make medical decisions or to alter screening schedules without consulting a healthcare professional. If you are concerned about your breast cancer risk, the most effective approach is to discuss your family history and personal health profile with a doctor or a genetic counselor, who can provide personalized guidance based on all relevant clinical factors.
How common is this variant?
The rs2981582 variant is common, with the minor allele frequency reported at approximately 40% in European populations.
Frequently asked questions
Does having the T allele mean I will get breast cancer?
No. This variant is a risk factor, meaning it is statistically associated with a higher likelihood of developing the disease, but it is not a direct cause. Many people with the T allele never develop breast cancer.
Should I get tested for rs2981582?
Genetic testing for common risk variants like rs2981582 is generally not recommended for routine clinical screening. You should discuss your overall breast cancer risk with a healthcare provider who can evaluate your family history and other clinical factors.
Is this the same as a BRCA mutation?
No. BRCA1 and BRCA2 mutations are rare, high-penetrance mutations that significantly increase breast cancer risk. rs2981582 is a common variant with a much smaller individual effect on risk.
Can I change my risk if I have the T allele?
While you cannot change your genetics, you can manage your overall health through lifestyle choices and regular screenings. Always follow the breast cancer screening guidelines recommended by your doctor based on your personal risk profile.
Sources & further reading
Educational information only, last refreshed 10/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2981582?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in FGFR2
Intronic variant in FGFR2 associated with increased risk of estrogen receptor-positive breast cancer.
This SNP is associated with an increased susceptibility to breast cancer.
This variant is associated with an increased risk of breast cancer in various populations.
This intronic variant in the FGFR2 gene has been associated with susceptibility to BRCA2-related breast cancer.
This variant is strongly correlated with prostate cancer aggressiveness and serum PSA levels.
Correlated genetic marker in the FGFR2 locus associated with altered prostate-specific antigen (PSA) levels and prostate cancer risk.